Skip to main content

Table 4 Summary of data abstraction and assessment notes for measurement properties and documentation using evaluation criteria by phase for patient-reported outcome measure-development across SLE-PRO measures

From: Capturing the patient experience in systemic lupus erythematosus: Are widely used measures fit-for-purpose and adherent to FDA PRO guidance recommendations?

 

LupusQoL

LupusQoL-US

LupusPRO v1.7

LupusPRO v1.8

Content validity

Item-generation

Limited details, lacking transparency; Evidence not sufficient to support measure adequacy

Limited details, lacking transparency; Evidence not sufficient to support measure adequacy

Limited details, lacking transparency; Evidence not sufficient to support measure adequacy

Limited details, lacking transparency; Evidence not sufficient to support measure adequacy

Cognitive interviewing

Limited details, lacking transparency

Limited details, lacking transparency

Limited details, lacking transparency

Limited details, lacking transparency

Other psychometric property testing

Reliability

Available

Available

Available

Available

Construct validity

Available

Available

Available

Available

Ability to detect change

Available

Not available

Available

Not available